REMS
185 results
1 - 100
REMS
Overview of Risk Evaluation and Mitigation Systems (REMS) - eculizumab
- tolvaptan
- mavacamten
- alvimopan
- fenfluramine
- ambrisentan
- pomalidomide
- bosentan
- thalidomide
- vigabatrin
- ISOtretinoin
- brodalumab
- pegvaliase
- zilucoplan
- metreleptin
- iptacopan
- miFEPRIStone
- crovalimab
- lomitapide
- Risk Evaluation and Mitigation Strategy
- teduglutide
- riociguat
- loxapine
- esketamine
- natalizumab
- ravulizumab
- OLANZapine
- sodium oxybate
- denosumab
- collagenase clostridium histolyticum
- phentermine/topiramate
- equivalent
- vandetanib
- mycophenolate mofetil
- elotuzumab
- dose
- panobinostat
- inotersen
- pexidartinib
- duvelisib
- teclistamab
- levorphanol
- melphalan
- alemtuzumab
- calcium oxybate/magnesium oxybate/potassium oxybate/sodium oxybate
- peginesatide
- elranatamab
- talquetamab
- daclizumab
- hydroxyurea
- nalbuphine
- lenalidomide
- ezogabine
- mipomersen
- parathyroid hormone
- butorphanol
- fentaNYL (transdermal)
- albiglutide
- meperidine
- oxyMORphone
- SUFentanil
- brexanolone
- buprenorphine
- HYDROmorphone
- methadone
- tapentadol
- buprenorphine/naloxone
- codeine
- oxyCODONE